Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Sanofi ( (SNY) ) has issued an announcement.
Sanofi has provided updated financial information reflecting its decision to transfer a 50% controlling stake in Opella, its consumer healthcare division, to CD&R. This move aligns with Sanofi’s strategy to transition into a focused, science-driven biopharma company. The reclassification of Opella’s business as discontinued operations is detailed in the income statements, and Sanofi’s Q4 2024 results, which will not include Opella, are set to be published on January 30, 2025. This strategic shift may impact the company’s operations and industry positioning, affecting stakeholders as Sanofi narrows its focus on biopharmaceuticals.
More about Sanofi
Sanofi is an innovative global healthcare company that operates in over 100 countries. It focuses on transforming medicine through science, offering life-changing treatments and vaccines, with an emphasis on sustainability and social responsibility. Sanofi is publicly traded on EURONEXT and NASDAQ.
YTD Price Performance: -2.63%
Average Trading Volume: 2,024,049
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $119.6B
For detailed information about SNY stock, go to TipRanks’ Stock Analysis page.
